Background: Parkinson's disease (PD) is a chronic, progressive, neurodegenerative disorder with currently no known cure. PD has a significant impact on quality of life of the patients, as well as, the caregivers and family members. It is the second most common cause of chronic neurological disability in US and Europe. According to National Parkinson's Foundation, there are almost 1 million patients in the Unites States and 50,000 to 60,000 new cases of PD are diagnosed each year. The total number of cases of PD is predicted to double by 2030. The annual cost associated with this disease is estimated to be $10.8 billion in the United States, including the cost of treatment and the cost of the disability. Although it is primarily thought of as a movement-disorder and is clinically diagnosed based on motor symptoms, non-motor symptoms such as cognitive and emotional deficits are thought to precede the clinical diagnosis by almost 20 years. By the time of clinical diagnosis, there is 80% loss in the dopamine content in the striatum and 50% degeneration of the substantia nigra dopamine cells. The research presented in this thesis was an attempt to develop an animal model of PD in its pre-motor stages. Such a model would allow us to develop pre-clinical markers for PD, and facilitate the development and testing of potential treatment strategies for the non-motor symptoms of the disorder. Specific Aims: There were five specific aims for this research: * The first specific aim dealt with development of a rat model of PD with slow, progressive onset of motor deficits, determination of timeline for future studies, and quantification the dopamine depletion in this model at a pre-motor stage. * The second and the third specific aims focused on testing for emotional (aversion) deficits and cognitive (executive functioning) deficits in this rat model at the 3 week timepoint determined during specific aim 1. * The fourth specific aim was to determine the brain network changes associated with the behavioral changes observed our rat model using resting state connectivity as a measure. * The fifth and the final specific aim was to test sodium butyrate, a drug from the histone deacetylase inhibitor family, as a potential treatment option for cognitive deficits in PD. Results: The 6-hydroxy dopamine based stepwise striatal lesion model of pre-motor PD, developed during this research, exhibits delayed onset of Parkinsonian gait like symptoms by week 4 after the lesions. At 3 weeks post lesion (3WKPD), the rats exhibit 27% reduction in striatal dopamine and 23%reduction in substantia nigra dopamine cells, with lack of any apparent motor deficits. The 3WKPD rats also exhibited changes in aversion. The fMRI study with the aversive scent pointed towards possible amygdala dysfunction sub-serving the aversion deficits. The executive function deficits tested using a rat analog of the Wisconsin card sorting test, divulged an extra-dimensional set shifting deficit in the 3WKPD rats similar to those reported in PD patients. The resting state connectivity study indicated significant changes in the 3WKPD rats compared to age matched controls. We observed increased overall connectivity of the motor cortex and increased CPu connectivity with prefrontal cortex, cingulate cortex, and hypothalamus in the 3WKPD rats compared to the controls. These observations parallel the observations in unmedicated early-stage PD patients. We also observed negative correlation between amygdala and prefrontal cortex as reported in humans. This negative correlation was lost in 3WKPD rats. Sodium butyrate treatment, tested in the cognitive deficit study, was able to ameliorate the extra-dimensional set shifting deficit observed in this model. This treatment also improved the attentional set formation. Conclusion: Taken together, our observations indicate that, the model of pre-motor stage PD developed during this research is a very high face validity rat model of late Braak stage 2 or early Braak stage 3 PD. Sodium butyrate was able to alleviate the cognitive deficits observed in our rat model. Hence, along with the prior reports of anti-depressant and neuroprotective effects of this drug, our results point towards a possible treatment strategy for the non-motor deficits of PD.

The most common cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation is δF508 and this causes cystic fibrosis (CF). Animal models that recapitulate the human disease phenotype are critical to understanding pathophysiologic mechanisms in CF and developing therapies. New CF models in the pig and ferret have been generated that develop lung, pancreatic, liver, and intestinal pathologies that reflect disease in CF patients. Species-specific biology in the processing of CFTR has demonstrated that pig and mouse δF508-CFTR proteins are more effectively processed to the apical membrane of airway epithelia than human δF508-CFTR. The processing behavior of ferret wild-type (WT) and δF508-CFTR proteins remain unknown and such information is important to predicting the utility of a δF508-CFTR ferret. To this end, we sought to compare processing, membrane stability, and function of human and ferret WT- and δF508-CFTR proteins in a heterologous expression system using HT1080, HEK293T, BHK21, and Cos7 cells, as well as human and ferret CF polarized airway epithelia. Analysis of the protein processing and stability by metabolic pulse-chase and surface On-Cell Western blots revealed that WT-fCFTR half-life and membrane stability were increased relative to WT-hCFTR. Furthermore, in BHK21, Cos7, and CuFi cells, human and ferret δF508-CFTR processing was negligible, while low levels of processing of δF508-fCFTR could be seen in HT1080 and HEK293T cells. Only the WT-fCFTR, but not δF508-fCFTR, produced functional cAMP-inducible chloride currents in both CF human and ferret airway epithelia. Further elucidation of the mechanism responsible for elevated fCFTR protein stability may lead to new therapeutic approaches to augment CFTR function. These findings also suggest that generation of a ferret CFTRδF508/δF508 animal model may be useful. Furthermore, in the CFTR and CFTR+/+ ferret model we have characterized abnormalities in the bioelectric properties of the trachea, stomach, intestine and gallbladder of newborn CF ferrets. Short circuit current (ISC) analysis of CF and WT tracheas revealed the following similarities and differences: 1) amiloride sensitive sodium currents were similar between genotypes, 2) responses to 4,4'-diisothiocyano-2,2'-stilbene disulphonic acid (DIDS) were ~4-fold greater in CF animals, suggesting elevated baseline chloride transport through non-CFTR channels, and 3) as expected, there was a lack of IBMX/forskolin-stimulated and GlyH-101-inhibited currents in CF animals due to the lack of CFTR. CFTR mRNA and protein was present throughout all levels of the WT ferret and IBMX/forskolin-inducible ISC was only observed in WT animals. Interestingly, IBMX/forskolin-inducible intestinal ISC in WT animals was not inhibited by the CFTR inhibitor GlyH-101 or bumetanide. The luminal pH of the CF ferret stomach was significantly decreased relative to the controls, while both genotypes maintained near neutral pH along the length of the intestine. The WT stomach and gallbladder exhibited significantly enhanced IBMX/forskolin ISC responses and inhibition by GlyH-101 relative to CF samples. These findings demonstrate that multiple organs affected by disease in the CF ferret have bioelectric abnormalities consistent with the lack of cAMP-mediated chloride transport.

Ocular hypertension has been identified as the fundamental risk factor in glaucoma which is the leading cause for irreversible blindness in the world. Understanding the different factors that affect IOP is of utmost importance in clinical management as IOP is considered as the fundamental factor in assessing the efficiency of glaucoma medications. Several studies have attempted to assess factors that could affect IOP including age, body position, blood pressure, anesthetics commonly used during eye operations, etc. However, in most of these studies IOP is measured under anesthesia using rodent models and these anesthetics could affect the IOP measurements directly or indirectly. The use of tonometry in such experiments also includes certain limitations like acquiring IOP at discrete moments in time, human error while handling the instrument and stress induced spikes in IOP while handling awake animals. This study uses a wireless continuously monitoring device to eliminate these limitations while also acquiring IOP at a higher rate. Anesthesia induction is known to lower body temperature. However, previous studies on the effects of various anesthetic agents fail to take into account this drop in body temperature which could potentially lead to erroneous results. This thesis focuses on studying the effects of two commonly used anesthetic agents, isoflurane and ketamine while accounting for loss in body temperature. The effects of changing body temperature on intraocular pressure was also studied to help understand the effects of these factors accurately. There was a statistically significant drop (p<0.001) in intraocular pressure post isoflurane induction with no heat support across several animals. The addition of heat support in the next set of experiments resulted in an almost steady pressure throughout the experiment. Since the body temperature was maintained constant throughout the experiment, there was no statistically significant difference (p>0.05) among IOP’s for the awake and anesthetized condition. This conclusion was then confirmed by obtaining a direct effect of changing body temperature on IOP. There was a rise in IOP while the animal was placed on a 42 degree Celsius heating pad and a drop in IOP while the animal was placed on a 20 degree Celsius surface with no heat support. The corresponding changes in body temperature were confirmed using a rectal thermometer. There were no significant changes in the IOP measured by the sensor while measuring pressure with the iCare tonolab. Applanation tonometry however produced an average mean intraocular pressure increase of 2.11 ± 1.62 mmHg.

Neuroblastoma, the most common extracranial solid tumor of childhood, is a heterogeneous tumor. In some patients, the tumor can go into spontaneous regression and disappear whereas other patients have rapidly growing tumors with a poor prognosis. The overall long-term survival rate in patients with high-risk neuroblastoma is less than 30%, indicating the need for new treatment strategies. Angiogenesis inhibition hampers the formation of new blood vessels, thereby limiting the tumors’ metabolic exchange. Neuroblastoma is rapidly growing and high tumor angiogenesis has been associated with poor outcome. Therefore, the aim of this thesis was to investigate the effect of novel treatment modalities for angiogenesis inhibition on high-risk neuroblastoma xenografts. For that purpose, we used subcutaneous mouse models and characterized orthotopic mouse models for high-risk neuroblastoma. We found that xenotransplantation of neuroblastoma cells into the adrenal gland of SCID and SCID beige mice resulted in orthotopic tumors resembling clinical neuroblastoma in respect to tumor site, growth and spread. Using contrast-enhanced ultrasound, we observed that the receptor tyrosine kinase inhibitor SU11248 reduced orthotopic neuroblastoma growth and spread by reducing tumor angiogenesis. In subcutaneous xenografts for high-risk neuroblastoma, valuable for studies requiring continuous assessment of tumor volume, we demonstrated that immune-neutralizing VEGF with the anti-VEGF antibody bevacizumab significantly reduced neuroblastoma growth. Finally, we found that formulations of the chemotherapeutic drug GMX1778 inhibited angiogenesis and induced tumor regression in a dose dependent manner without host toxicity. We showed that relapsing tumors remained responsive to GMX-therapy without accelerated growth or induced drug resistance. In conclusion, SU11248, bevacizumab, and formulations of the active compound GMX1778 may become useful for treating high-risk neuroblastoma.

The major objectives of this research were to produce a phenolic rich isolate from two locally grown Saskatchewan fruits, chokecherries and saskatoons, develop an encapsulation system for the phenolic isolate, and test this system for the delivery of the phenolic isolate in an animal (rat) model. Natural phenolic compounds present in plants such as fruits have antioxidant and free radical scavenging activities, which have been proposed to have health benefits. The extraction of these compounds from plants is commonly performed using methanol despite being toxic to both humans and animals. As such, ethanol was investigated for its ability to extract phenolics from plants as a food safe alternative to methanol. Phenolic extraction from chokecherries with ethanol:formic acid:water (EFW) resulted in higher concentrations (9.83 mg gallic acid equivalents (GAE)/g fresh weight) than with methanol:formic acid:water (MFW) (7.97 mg GAE/g fresh weight). Results from saskatoons showed similar phenolic levels of 4.26 and 4.21 mg GAE/g fresh weight with MFW and ethanol (EFW), respectively. These results showed that EFW was a suitable substitute for MFW in phenolic compound isolation from chokecherries and saskatoons, and could be used to produce extracts that were safe for use in foods and feeds. High performance liquid chromatography with photodiode array detection (HPLC-PDA) was used to determine the phenolic compound composition of the raw fruits and their phenolic rich isolates. Chlorogenic acid was identified in both chokecherry and saskatoon samples, and rutin was also shown to be present in saskatoons. These identifications were based on the relative retention time and ultra violet-visual spectra comparisons to standards. Solid phase extraction (SPE) using Amberlite XAD-16 was employed to produce phenolic isolates from chokecherries and saskatoons. HPLC-PDA results determined that there was a ~2.7x and ~1.6x increase in peak area for chokecherries and saskatoons, respectively when SPE was employed. The antioxidant activity of the extracts and isolates was determined using in vitro radical scavenging tests including 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2´-azinobis-3-ethylbenzthiazoline-sulphonic acid (ABTS). The EFW chokecherry extract and isolate had the highest overall free radical scavenging activity. Crude fruit extracts exhibited lower free radical scavenging values compared to the isolate samples in both of the assays performed. The fruit phenolic isolates were encapsulated in chitosan (CH) sodium tripolyphosphate (TPP) nanoparticles at a ratio of 4.0:1.0 (CH:TPP). HPLC-PDA was used to determine the entrapment efficiency of phenolic isolates to be 15.9 ± 2.7% and 23.0 ± 7.1% for chokecherries and saskatoons, respectively. Characteristics such as the size, surface potential and phenolic release were determined for the two fruit isolate containing nanoparticles. The size of the nanoparticles were 527.90 ± 74.57 nm and 443.03 ± 15.79 nm for chokecherries and saskatoons, respectively. Both of the nanoparticle systems had positive surface charges at 52.70 ± 2.93 mV and 54.43 ± 1.27 mV for chokecherries and saskatoons, respectively. The release properties of the CH:TPP nanoparticles containing fruit phenolics were examined in enzymatic simulated intestinal fluid and resulted in ~23% and ~28% release of chokecherry and saskatoon phenolics, respectively. Saskatoon phenolic isolates and isolates encapsulated in CH:TPP were gavage fed to rats (six animals in each of the two groups) at a dosage rate of 276.36 ± 9.74 mg/kg body weight. The saskatoon isolate contained 12.44 ± 0.44 mg/kg body weight anthocyanins (~3.30 mg anthocyanin per rat). These animals were sacrificed after 1 h and all stomach tissue samples in each of the treatment groups contained detectable levels of anthocyanins. In the small intestine tissues all six of the saskatoon isolate and three of the encapsulated isolate groups had detectable amounts of anthocyanins, while in the large intestine tissue, only one sample from the isolate group showed detectable amounts of anthocyanins. Although other tissues were tested (brain, heart, kidney and liver), anthocyanins were not detected. Therefore anthocyanins were detected in the gastrointestinal tract of both of the treatment groups. The research performed therefore illustrated that phenolic compounds can be extracted from fruit sources using EFW and can be successfully encapsulated in chitosan tripolyphosphate capsules allowing for targeted delivery in an animal model.

Renal cell carcinoma (RCC) is the commonest urogenital tumor, characterized by increased expression of hypoxia inducible factors (HIFs). During normoxia, HIFα subunits are targeted for proteasomal degradation by the product of the von Hippel Lindau gene (pVHL). In RCC, mutations in the VHL gene allow the HIFα subunits to escape degradation and translocate to the nucleus where they activate transcription of their target genes. Although both HIF1α and HIF2α are upregulated in RCC, it has been suggested that HIF2α plays the dominant role. To further elucidate the function of HIF2α in RCC, we generated a transgenic mouse model that permits temporal stabilization of HIF2α in renal tubular cells. Induction of HIF2α results in the rapid development of renal cysts - a feature observed in RCC. Taken together, these results suggest that HIF2α is a key player in development of RCC and an excellent candidate target for therapy in this disorder.

In this thesis I used Caenorhabitis elegans as a model of Fetal Alcohol Spectrum Disorder (FASD) to study the physical and behavioral effects of ethanol exposure during embryonic development. Davis et al. (2008) found that ethanol exposure during larval development in C. elegans produced physical/developmental and behavioral effects; however, whether exposure during embryonic development might produce similar outcomes remained to be elucidated. Because the type and degree of effects caused by developmental ethanol exposure was dependent on the pattern of ethanol treatment, in the first part of the thesis I investigated the physical/developmental effects of embryonic exposure to various ethanol doses, exposure durations, onsets and frequencies. I found that exposure to >30% ethanol for an hour during embryonic development was necessary to lower hatch rate, delay reproductive onset, and reduce body size in C. elegans. Furthermore, exposure during early embryonic development caused a larger effect than exposure during later stages, and multiple exposures produced a worse outcome than a single exposure for a comparable duration. In the second part of the thesis, I investigated locomotory activities and habituation of adult C. elegans exposed to various patterns of embryonic ethanol treatment. I found that the rate of locomotion was altered differently by chronic and acute embryonic ethanol exposure, but I did not find any effect in short- or long-term habituation. In summary, I have characterized the pattern of embryonic ethanol exposure necessary to produce physical/developmental effects in C. elegans, and identified the types of exposure conditions that would cause worse outcomes than others; in addition, I have found that embryonic ethanol exposure affects the rate of locomotion in C. elegans. In this thesis, I have established a foundation for the future investigation into the physical and motor defects caused by embryonic ethanol exposure in C. elegans.

Myopia is a common ocular condition worldwide and the mechanism of myopia is still not clear. A number of animal models of myopia and refractive error development have been proposed. The fact that form deprivation myopia could be induced in tilapia fish, as shown previously in my research, suggests the possibility that tilapia could be a new animal model for myopia research. In the first part of this thesis the tilapia model was perfected and then, based on this model, the effect of systemic hormones (thyroid hormones) associated with eye and body development was investigated during refractive error development. Lastly, the physiological and morphological changes on the retina were further studied with optical coherence tomography (OCT). In these experiments, significant amounts of myopia, and hyperopia were induced within two weeks using goggles with lens inserts as in other higher vertebrate animal models, e.g. chicks. The results from form deprivation treatment also show that the sensitivity of tilapia eyes may be an age related effect during the emmetropization process. The larger the fish, the less hyperopic the fish eye, though the small eye artefact may be a factor. The susceptibility of the refractive development of the eye to the visual environment may be also linked to plasma hormone levels. It was found that induced refractive errors could be shifted in the hyperopic direction with high levels of thyroid hormones. Also, after 2 weeks of treatment with negative or positive lens/goggles, the tilapia retina becomes thinner or thicker, respectively. When the goggles are removed, the thickness of the retina changes within hours and gradually returns to normal. However, the circadian retinomotor movement is a complicating factor since it affects the retinal thickness measurement with OCT at some time points. In conclusion, tilapia represent a good lower vertebrate model for myopia research, suggesting a universal mechanism of myopia development, which may involve systemic hormones and immediate, short term retinal responses.

Myopia is a common ocular condition worldwide and the mechanism of myopia is still not clear. A number of animal models of myopia and refractive error development have been proposed. The fact that form deprivation myopia could be induced in tilapia fish, as shown previously in my research, suggests the possibility that tilapia could be a new animal model for myopia research. In the first part of this thesis the tilapia model was perfected and then, based on this model, the effect of systemic hormones (thyroid hormones) associated with eye and body development was investigated during refractive error development. Lastly, the physiological and morphological changes on the retina were further studied with optical coherence tomography (OCT). In these experiments, significant amounts of myopia, and hyperopia were induced within two weeks using goggles with lens inserts as in other higher vertebrate animal models, e.g. chicks. The results from form deprivation treatment also show that the sensitivity of tilapia eyes may be an age related effect during the emmetropization process. The larger the fish, the less hyperopic the fish eye, though the small eye artefact may be a factor. The susceptibility of the refractive development of the eye to the visual environment may be also linked to plasma hormone levels. It was found that induced refractive errors could be shifted in the hyperopic direction with high levels of thyroid hormones. Also, after 2 weeks of treatment with negative or positive lens/goggles, the tilapia retina becomes thinner or thicker, respectively. When the goggles are removed, the thickness of the retina changes within hours and gradually returns to normal. However, the circadian retinomotor movement is a complicating factor since it affects the retinal thickness measurement with OCT at some time points. In conclusion, tilapia represent a good lower vertebrate model for myopia research, suggesting a universal mechanism of myopia development, which may involve systemic hormones and immediate, short term retinal responses.

The major objectives of this research were to produce a phenolic rich isolate from two locally grown Saskatchewan fruits, chokecherries and saskatoons, develop an encapsulation system for the phenolic isolate, and test this system for the delivery of the phenolic isolate in an animal (rat) model. Natural phenolic compounds present in plants such as fruits have antioxidant and free radical scavenging activities, which have been proposed to have health benefits. The extraction of these compounds from plants is commonly performed using methanol despite being toxic to both humans and animals. As such, ethanol was investigated for its ability to extract phenolics from plants as a food safe alternative to methanol. Phenolic extraction from chokecherries with ethanol:formic acid:water (EFW) resulted in higher concentrations (9.83 mg gallic acid equivalents (GAE)/g fresh weight) than with methanol:formic acid:water (MFW) (7.97 mg GAE/g fresh weight). Results from saskatoons showed similar phenolic levels of 4.26 and 4.21 mg GAE/g fresh weight with MFW and ethanol (EFW), respectively. These results showed that EFW was a suitable substitute for MFW in phenolic compound isolation from chokecherries and saskatoons, and could be used to produce extracts that were safe for use in foods and feeds. High performance liquid chromatography with photodiode array detection (HPLC-PDA) was used to determine the phenolic compound composition of the raw fruits and their phenolic rich isolates. Chlorogenic acid was identified in both chokecherry and saskatoon samples, and rutin was also shown to be present in saskatoons. These identifications were based on the relative retention time and ultra violet-visual spectra comparisons to standards. Solid phase extraction (SPE) using Amberlite XAD-16 was employed to produce phenolic isolates from chokecherries and saskatoons. HPLC-PDA results determined that there was a ~2.7x and ~1.6x increase in peak area for chokecherries and saskatoons, respectively when SPE was employed. The antioxidant activity of the extracts and isolates was determined using in vitro radical scavenging tests including 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2´-azinobis-3-ethylbenzthiazoline-sulphonic acid (ABTS). The EFW chokecherry extract and isolate had the highest overall free radical scavenging activity. Crude fruit extracts exhibited lower free radical scavenging values compared to the isolate samples in both of the assays performed. The fruit phenolic isolates were encapsulated in chitosan (CH) sodium tripolyphosphate (TPP) nanoparticles at a ratio of 4.0:1.0 (CH:TPP). HPLC-PDA was used to determine the entrapment efficiency of phenolic isolates to be 15.9 ± 2.7% and 23.0 ± 7.1% for chokecherries and saskatoons, respectively. Characteristics such as the size, surface potential and phenolic release were determined for the two fruit isolate containing nanoparticles. The size of the nanoparticles were 527.90 ± 74.57 nm and 443.03 ± 15.79 nm for chokecherries and saskatoons, respectively. Both of the nanoparticle systems had positive surface charges at 52.70 ± 2.93 mV and 54.43 ± 1.27 mV for chokecherries and saskatoons, respectively. The release properties of the CH:TPP nanoparticles containing fruit phenolics were examined in enzymatic simulated intestinal fluid and resulted in ~23% and ~28% release of chokecherry and saskatoon phenolics, respectively. Saskatoon phenolic isolates and isolates encapsulated in CH:TPP were gavage fed to rats (six animals in each of the two groups) at a dosage rate of 276.36 ± 9.74 mg/kg body weight. The saskatoon isolate contained 12.44 ± 0.44 mg/kg body weight anthocyanins (~3.30 mg anthocyanin per rat). These animals were sacrificed after 1 h and all stomach tissue samples in each of the treatment groups contained detectable levels of anthocyanins. In the small intestine tissues all six of the saskatoon isolate and three of the encapsulated isolate groups had detectable amounts of anthocyanins, while in the large intestine tissue, only one sample from the isolate group showed detectable amounts of anthocyanins. Although other tissues were tested (brain, heart, kidney and liver), anthocyanins were not detected. Therefore anthocyanins were detected in the gastrointestinal tract of both of the treatment groups. The research performed therefore illustrated that phenolic compounds can be extracted from fruit sources using EFW and can be successfully encapsulated in chitosan tripolyphosphate capsules allowing for targeted delivery in an animal model.